News
BGP advises the shareholders of PharmaSwiss AG
01. February 2011
Bader Gnehm & Partner, Attorneys-at-law, advised the shareholders of PharmaSwiss Ltd. regarding the sale of PfarmaSwiss Ltd. for EUR 350 million to Valeant Pharmaceuticals International, Inc.
Bader ▪ Gnehm & Partner has been recognized by the Regulatory Board of the Swiss stock exchange SIX Swiss Exchange AG as competent representative in the product area of equity securities.
01. August 2010
The recognition allows Bader ▪ Gnehm & Partner to represent issuers and their representatives in connection with submitting listing applications (e.g. regarding IPOs or capital increases) vis-à-vis the SIX Swiss Exchange. The recognition has been granted to us due to our professional knowledge and experience regarding the Swiss company and stock exchange law.
Statement for the attention of the Swiss Takeover Board regarding the exemption form share buy-back programs
07. June 2009
Statement by Bader Gnehm & Partner regarding the draft revision of circular Nr. 1 by the Swiss Takeover Board regarding exemption form share buy-back programs.